There are currently 4 ongoing clinical trials involving Alagille Syndrome
Of the 4 trials,3 trials are in Phase II
Furthermore, 1 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Alagille Syndrome, a genetic disorder. North America and Europe are among some of the prominent regions involved in Alagille Syndrome-related drug trials.
Alagille Syndrome related clinical trials sponsors
Mirum Pharmaceuticals Inc, and Albireo Pharma Inc are a few notable sponsors for clinical trials involving Alagille Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drug involving Alagille Syndrome
Maralixibat chloride (Livmarli) is a key marketed drug involving Alagille Syndrome.
Maralixibat chloride (Livmarli) is an anti-pruritus agent. It functions via Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Inhibitor mechanism of action. It is formulated as solution for oral route of administration. Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older. Livmarli received first approval in 2021 and is marketed in the US by Mirum Pharmaceuticals Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward